All In Biotech

Drug Trial Radar · NCT05192382

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

111

Actual

Start

Dec 17, 2021

Primary completion

Jan 20, 2024

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

Conditions

  • Acromegaly

Interventions

  • PaltusotineDrug

    Paltusotine, tablets, once daily by mouth

  • PlaceboDrug

    Placebo, tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Biochemical Response in Insulin-like Growth Factor-1 (IGF-1) at the End of the Randomized Control Phase (EOR)Time frame: Week 24

Locations

57 sites in 15 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Aurora, Colorado

  • Crinetics Study Site

    Boston, Massachusetts

  • Crinetics Study Site

    Columbus, Ohio

  • Crinetics Study Site

    Portland, Oregon

  • Crinetics Study Site

    Philadelphia, Pennsylvania

  • Crinetics Study Site

    Pittsburgh, Pennsylvania

  • Crinetics Study Site

    Buenos Aires, Argentina

  • Crinetics Study Site

    CABA, Argentina

  • Crinetics Study Site

    CABA, Argentina

  • Crinetics Study Site

    Córdoba, Argentina

  • Crinetics Study Site

    CABA, Buenos Aires, Argentina

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    São Paulo, Brazil

  • Crinetics Study Site

    São Paulo, Brazil

  • Crinetics Study Site

    Fortaleza, Ceará, Brazil

  • Crinetics Study Site

    Belo Horizonte, Minas Gerais, Brazil

  • Crinetics Study Site

    Curitiba, Paraná, Brazil

  • Crinetics Study Site

    Botucatu, São Paulo, Brazil

  • Crinetics Study Site

    Campinas, São Paulo, Brazil

  • Crinetics Study Site

    Sofia, Bulgaria

  • Crinetics Study Site (b)

    Beijing, Beijing Municipality, China

  • Crinetics Study Site

    Guangzhou, Guangdong, China

  • Crinetics Study Site

    Shijiazhuang, Hebei, China

  • Crinetics Study Site

    Zhengzhou, Henan, China

  • Crinetics Study Site

    Wuhan, Hubei, China

  • Crinetics Study Site

    Changsha, Hunan, China

  • Crinetics Study Site

    Jinan, Shandong, China

  • Crinetics Study Site

    Xi’an, Shanxi, China

  • Crinetics Study Site

    Chengdu, Sichuan, China

  • Crinetics Study Site

    Hangzhou, Zhejiang, China

  • Crinetics Study Site

    Marseille, France

  • Crinetics Study Site

    Pessac, France

  • Crinetics Study Site

    Toulouse, France

  • Crinetics Study Site

    Aachen, Germany

  • Crinetics Study Site

    Berlin, Germany

  • Crinetics Study Site

    München, Germany

  • Crinetics Study Site

    München, Germany

  • Crinetics Study Site

    Würzburg, Germany

  • Crinetics Study Site

    Athens, Greece

  • Crinetics Study Site (b)

    Athens, Greece

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.